BioWorld

Oct. 12, 2007

Cortex Falls As FDA Rejects CX717 Phase IIb In ADHD

Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today) Read More

Missed Endpoint Won't Doom Future of Gattex, NPS Vows

CombinatoRx Stock Offering Nets $33M For Thick Pipeline

Hemispherx Files Ampligen NDA: First Therapy For CFS?

Pharmaxis Raises $45M To Push Late-Stage Pulmonary Drugs

CuraGen Shuts Down Program Following 2nd Phase II Failure

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...